Back to Journals » Biologics: Targets and Therapy » Volume 12

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease

Authors Matsumoto S, Mashima H

Received 26 March 2018

Accepted for publication 9 June 2018

Published 19 July 2018 Volume 2018:12 Pages 69—73

DOI https://doi.org/10.2147/BTT.S169326

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Doris Benbrook


Satohiro Matsumoto, Hirosato Mashima

Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

Abstract: Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn’s disease. However, some problems have been identified during clinical use of this class of drugs, such as secondary treatment failure, in which the drugs become progressively less effective with time, and the development of paradoxical reactions such as psoriatic skin symptoms. Thus, while anti-TNFα drugs are used to treat psoriasis, they can sometimes also cause paradoxical psoriasis, characterized by the appearance of psoriasis-like eruptions, which has recently begun to attract attention. Furthermore, inflammatory bowel disease is not only associated with intestinal lesions, but also with a variety of extraintestinal manifestations, of which arthritis is relatively common. We encountered a case of Crohn’s disease with arthritis, as an extraintestinal manifestation, and paradoxical psoriasis caused by infliximab treatment, in which ustekinumab proved extremely effective, not only for alleviating the arthritis, but also against the skin manifestations. To the best of our knowledge, this is the first reported case of the efficacy of ustekinumab against paradoxical psoriasis and arthritis in a patient with Crohn’s disease.

Keywords: ustekinumab, paradoxical psoriasis, infliximab, arthritis, Crohn’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]